Complications of CKD and Their Management
The major complications of CKD requiring active management are: progressive kidney disease/albuminuria, cardiovascular disease, metabolic acidosis, hyperkalemia, anemia, and mineral-bone disorders—each requiring specific pharmacologic interventions and monitoring protocols based on the 2024 KDIGO guidelines 1.
1. Progressive Kidney Disease & Albuminuria
Standard Regimen (Foundational Therapies)
SGLT2 Inhibitors - First-line nephroprotection 1:
- eGFR ≥20 with ACR ≥200 mg/g OR heart failure (any albuminuria): Strong recommendation (1A)
- eGFR 20-45 with ACR <200 mg/g: Conditional recommendation (2B)
- Continue even if eGFR drops below 20 unless dialysis initiated
RAS Inhibitors (ACEi/ARB) - For albuminuria >30 mg/g 1:
- Titrate to maximum tolerated dose
- Essential foundation before adding other agents
Nonsteroidal MRA (Finerenone) - For T2D patients 1:
- Indication: eGFR >25, normal potassium, ACR >30 mg/g despite maximal RASi
- Can be added to RASi + SGLT2i combination
Drug Monitoring - SGLT2 Inhibitors 1
Key Clinical Pearl: The initial eGFR drop (typically 5-10%) is expected and NOT a reason to discontinue—this represents hemodynamic adaptation, not kidney injury 1.
- No need to increase monitoring frequency after initiation
- Withhold during: prolonged fasting, surgery, critical illness (ketosis risk)
- Monitor for genital mycotic infections, volume depletion
Drug Monitoring - Nonsteroidal MRA (Finerenone) 1
Dosing Algorithm:
| Baseline K+ | Action |
|---|---|
| ≤4.8 mmol/L | • Initiate: 10 mg daily (eGFR 25-59) OR 20 mg daily (eGFR ≥60) • Check K+ at 1 month, then every 4 months • Uptitrate to 20 mg if on 10 mg and K+ remains ≤4.8 |
| 4.9-5.5 mmol/L | • Continue current dose • Monitor K+ every 4 months |
| >5.5 mmol/L | • HOLD finerenone • Adjust diet/medications • Recheck K+ • Restart 10 mg when K+ ≤5.0 |
Contraindications:
- eGFR ≤25 ml/min/1.73 m²
- Baseline hyperkalemia (K+ >5.5)
- Concurrent potassium-sparing diuretics or strong CYP3A4 inhibitors
Special Considerations - GLP-1 RA 1
For T2D patients not at glycemic target despite metformin + SGLT2i:
- Use long-acting GLP-1 RA with proven cardiovascular benefits (1B)
- Provides additional nephroprotection and CV risk reduction
2. Cardiovascular Disease
Standard Regimen
Statins - Universal recommendation for CV risk reduction 2:
- Indicated for all CKD patients to reduce atherosclerotic CVD
- Note: Efficacy diminishes in stages 4-5 CKD but still recommended in earlier stages 3
Blood Pressure Control:
- Target individualized based on albuminuria and comorbidities
- RASi preferred for dual BP/proteinuria benefit
3. Metabolic Acidosis
Standard Regimen 1
Indication: Consider treatment when bicarbonate <18 mmol/L to prevent clinical complications
Dosing:
- Sodium bicarbonate: 1-2 heaped teaspoons 2-3 times daily 3
- Inexpensive, safe, does not raise BP despite sodium content
Drug Monitoring 1
- Target: Maintain bicarbonate within normal range (do NOT exceed upper limit)
- Monitor: BP, serum potassium, fluid status
- Avoid over-correction which can worsen outcomes
Clinical Pearl: Chronic acidosis accelerates CKD progression—treatment is mandatory, not optional 3.
4. Hyperkalemia
Management Algorithm 1
Non-emergent hyperkalemia:
Dietary modification 1:
- Limit bioavailable potassium (especially processed foods)
- Individualized approach with renal dietitian for CKD G3-G5
Medication adjustment:
- Review and adjust K+-raising medications
- Consider potassium binders if needed (local formulary dependent)
Continue nephroprotective agents when possible:
- Don't reflexively stop RASi/MRA for mild elevations
- Use algorithm above for finerenone management
Special Considerations 1
Critical awareness: Potassium measurements vary with:
- Diurnal and seasonal variation
- Plasma vs. serum samples
- Medication effects
- Hemolysis artifact
Clinical Pearl: A single elevated K+ should be confirmed before making major medication changes, especially if discontinuing nephroprotective therapy.
5. Anemia
Standard Regimen 3
Target hemoglobin: 10-12 g/dL per international guidelines
Management:
- Erythropoiesis-stimulating agents (ESAs)
- Iron supplementation (IV often superior in CKD)
- Address secondary hyperparathyroidism (worsens anemia resistance)
6. Mineral-Bone Disorders
Key Complications 3
Hyperphosphatemia (especially stages 4-5):
- Associated with vascular calcification, CAD, MI, stroke
- Phosphate binders required
- Dietary phosphate restriction
Secondary Hyperparathyroidism:
- Major CV risk factor
- Worsens hypertension and anemia resistance
- Requires vitamin D analogs, calcimimetics
7. Hyperuricemia/Gout 1
Standard Regimen
Symptomatic hyperuricemia: Offer uric acid-lowering therapy (1C)
Initiation criteria:
- After first gout episode (especially if no precipitant OR uric acid >9 mg/dL [535 μmol/L])
Agent selection:
- Xanthine oxidase inhibitors preferred over uricosurics in CKD
Clinical Pearl: Asymptomatic hyperuricemia does NOT require treatment for nephroprotection 4.
Critical Contraindications & Pitfalls
Nephrotoxin Avoidance 2, 5
Absolute avoidance:
- NSAIDs (major cause of AKI in CKD)
- Aminoglycosides when alternatives exist
- IV contrast without prophylaxis
Sick Day Medication Management 5:
- Educate patients to hold RASi, diuretics, SGLT2i, NSAIDs during acute illness with volume depletion
- Critical for preventing AKI
Drug Dosing Adjustments 2, 5
Require dose adjustment:
- Most antibiotics
- Oral hypoglycemics (especially sulfonylureas, metformin)
- Many cardiovascular medications
- Use validated eGFR equations for dosing decisions
Monitoring Schedule Summary
| Parameter | Frequency |
|---|---|
| eGFR & albuminuria | Every 3-12 months (based on stage) |
| Potassium (on MRA) | 1 month after initiation, then every 4 months |
| Bicarbonate | Every 3-6 months in stages 3-5 |
| Hemoglobin | Every 3-6 months in stages 3-5 |
| Phosphate, PTH, vitamin D | Every 6-12 months in stages 3-4; every 3-6 months in stage 5 |
The modern CKD management paradigm has shifted from reactive complication management to proactive multi-drug nephroprotection (RASi + SGLT2i ± MRA ± GLP-1 RA) combined with vigilant monitoring and nephrotoxin stewardship 1, 5.